Investors focused on the Medical space have likely heard of Biogen (BIIB Quick QuoteBIIB - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Biogen is one of 758 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. BIIB is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for BIIB's full-year earnings has moved 6.34% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Our latest available data shows that BIIB has returned about 7.65% since the start of the calendar year. At the same time, Medical stocks have gained an average of 5.14%. This shows that Biogen is outperforming its peers so far this year.

Breaking things down more, BIIB is a member of the Medical - Biomedical and Genetics industry, which includes 280 individual companies and currently sits at #103 in the Zacks Industry Rank. Stocks in this group have lost about 2.42% so far this year, so BIIB is performing better this group in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track BIIB. The stock will be looking to continue its solid performance.